NantHealth, Inc. provides clinical policy guidelines on radiation oncology treatments and oncology drug regimens. These drug regimens contain chemotherapeutic agents as well as supportive drugs utilized in conjunction with chemotherapy. These policies are primarily based on the National Comprehensive Cancer Network® (NCCN) oncology standards as well as the U.S. Food and Drug Administration (FDA) standards. NCCN consensus clinical standards are periodically updated, and NantHealth, Inc. reviews these and updates its policies within a timely manner. They are, at a minimum, reviewed annually if there are no periodic updates during the year from the NCCN or the U.S. FDA. Providers and Members can view Nanthealth’s oncology policies and guidelines for informational purposes as well as standards regarding dosages and treatment.
Procedure codes appearing in medical policy documents are only included as a general reference. The list may not be all-inclusive and is subject to updates. In addition, codes listed are not a guarantee of payment. The dosing tables in the policies represent evidence-based doses for the designated type of cancer drug or treatment. Variations outside of the ranges may indicate a deviation from standard treatments.
For any questions regarding these policies, please contact:
NantHealth, Inc.
1735 Market Street, Suite 1300
Philadelphia, PA 19103
888-482-8057, Option 2
Radiation Therapy
- Anal Cancer
- Bladder Cancer
- Bone Metastases
- Brachytherapy
- Breast Cancer
- Central Nervous System Cancer
- Colon Rectal Cancer
- Esophageal and Gastric Cancer
- External Beam Radiation Treatment
- Gynecologic Cancers
- Head and Neck Cancer
- Image-Guided Radiation Therapy
- Intensity Modulated Radiation Therapy
- Liver and Biliary Tract Cancer
- Lung Cancer
- Lymphoma
- Other Cancers
- Pancreatic Cancer
- Primary Bone Cancer
- Prostate Cancer
- Proton Beam Therapy
- Selective Internal Radiation Therapy
- Skin Cancer
- Soft Tissue Sarcoma
- Stereotactic Body Radiation Therapy
- Stereotactic Radiosurgery
- Three Dimensional Confirmation Radiation
Medical Oncology
- Ado-Trastuzumab Emtansine NEW
- Aldesleukin
- Amivantamab-vmjw
- Arsenic Trioxide
- Atezolizumab
- Avelumab
- Axicabtagene Ciloleucel
- Belinostat
- Bendamustine HCL
- Bevacizumab and Biosimilars
- Blinatumomab
- Bortezomib
- Brentuximab Vedotin
- Brexucabtagene Autoleucel
- Cabazitaxel
- Carfilzomib
- Cemiplimab-rwlc
- Cetuximab
- Ciltacabtagene Autoleucel
- Daratumumab
- Daratumumab and Hyaluronidase-fihj
- Dostarlimab-gxly
- Durvalumab
- Enfortumab Vedotin-ejfv
- General Oncology Drugs
- Glofitamab-gxbm
- Idecabtagene Vicleucel
- Lenalidomide NEW
- Lenvatinib Mesylate NEW
- Lifileucel NEW
- Lisocabtagene Maraleucel
- Lurbinectedin
- Nivolumab and relatlimab-rmbw
- Nogapendekin alfa inbakicept-pmln NEW
- Paclitaxel albumin-bound
- Panitumumab
- Pegfilgrastim and Biosimilars
- Pertuzumab
- Ramucirumab
- Sacituzumab govitecan-hziy
- Tisagenlecleucel
- Trastuzumab and biosimilars
- Tremelimumab-actl
- Trilaciclib
- Ziv-aflibercept
- Zoledronic Acid